Molecular and Biochemical Screening for the Diagnosis and Management of Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasia Type 2A

Abstract

Patients with multiple endocrine neoplasia (MEN) type 2A are at risk for early medullary thyroid carcinoma (MTC). We performed different screening tests for MTC - a recently reported biochemical screening test using omeprazole-induced calcitonin (CT) stimulation and DNA analysis - in fifteen members of two non-consanguineous Brazilian families with MEN 2A. RET proto-oncogene analysis was carried out by direct DNA sequencing of PCR-amplified products for exons 10 and 11. Family 1 showed a germline mutation (C634Y) in three individuals; a sister and a brother with symptomatic MTC; the former also presented with pheochromocytoma and hyperparathyroidism, and her son was a nine-year-old boy of previously unknown status. Family 2 showed the C634R mutation only in the index case, who presented with cutaneous lichen amyloidosis in addition to MTC, pheochromocytoma and hyperparathyroidism. Neither her parents nor her four brothers showed this genetic abnormality, suggesting a de novo RET proto-oncogene mutation in this patient. The controls and patients presented normal basal gastrin levels and a significant increase after omeprazole. Basal CT levels were elevated in patients with MTC and undetectable in control and asymptomatic family members. No subject showed any increase in CT levels after omeprazole treatment. In conclusion, the two most frequent RET proto-oncogene mutations in MEN 2A are present in Brazilian families. In addition, the specificity of basal and omeprazole-stimulated calcitonin is rather limited, and the efficacy of the omeprazole test still needs to be systematically examined. Therefore, RET proto-oncogene analysis must be the first choice for a screening procedure to identify gene carriers in MEN 2A family members and to permit early prophylactic treatment of MTC.

RET Proto-Oncogene - Mutation - Endocrine Neoplasia - Screening

References

• 1 Sipple J H. The association of pheochromocytomas with carcinoma of the thyroid gland.  Am J Med . 1961;  31 163-166
• 2 Steiner A L, Goodman A D, Powers S R. Study of kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2.  Medicine (Baltimore). 1968;  47 371-409
• 3 Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations.  Mol Cell Biol. 1995;  15 1613-1619
• 4 Wohlk N, Cote G J, Evans D B, Goepfert H, Ordonez N G, Gagel R F. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2.  Endocrinol Metab Clin North Am. 1996;  25 1-25
• 5 Kakudo K, Carney J A, Sizemore G W. Medullary carcinoma of thyroid: Biologic behavior of the sporadic and familial neoplasm.  Cancer. 1985;  55 2818-2821
• 6 Wells S A, Baykub S B, Linehan W M. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland.  Ann Surg. 1978;  188 139-141
• 7 Wells S A , Chi D D, Toshima K, Dehner L P, Coffin C M, Dowton S B, Ivanovich J L, DeBenedetti M K, Dilley W G, Moley J F. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.  Ann Surg. 1994;  220 237-250
• 8 Erdogan M F, Gullu S, Baskal N, Uysal A R, Kamel N, Erdogan G. Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma.  J Clin Endocrinol Metab. 1997;  82 897-899
• 9 Mulligan L M, Kwok J BJ, Healey C S, Elsdon M J, Eng C, Gardner E. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A).  Nature. 1993;  363 458-460
• 10 Eng C, Mulligan L M. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease.  Hum Mutat. 1997;  9 97-109
• 11 Bongarzone I, Monzini N, Borrello M G, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della P orta, Pierotti M A. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of RET tyrosine kinase and regulatory subunit RI of cyclic AMP-dependent protein kinase A.  Mol Cell Biol. 1993;  13 358-366
• 12 Kwok J BJ, Gardner E, Warner J P, Ponder B AJ, Mulligan L M. Structural analysis of the human RET proto-oncogene by exon trapping.  Oncogene. 1993;  8 2572-2582
• 13 Lorenzo M J, Eng C, Mulligan L M, Stonehouse T J, Healey C S, Ponder B A, Smith D P. Multiple mRNA isoforms of the human RET proto-oncogene generated by alternate splicing.  Oncogene. 1995;  10 1377-1383
• 14 Myers S M, Enc C, Ponder V AJ, Mulligan L M. Characterization of RET proto-ooncogene 3’ splicing variants and polyadenylation sites: a novel C-terminal for RET.  Oncogene. 1995;  11 2039-2045
• 15 Santoro M, Rosati R, Grieco M, Berlingieri M T, D’Amato G L, de Franciscis V, Fusco A. The RET proto-oncogene is consistently expressed in human pheochromocytoma and thyroid medullary carcinomas.  Oncogene. 1990;  5 1595-1598
• 16 Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the RET proto-oncogene product in human normal and neoplasic tissues of neural crest origin.  J Pathol. 1994;  172 255-260
• 17 Siegelman M, Mohabeer A, Fahey T J 3rd, Tomlinson G, Mayambala C, Jafari S, Noll W W, Thibodeau S N, Dawson D B. Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET proto-oncogene associated with inherited medullary thyroid carcinoma.  Clin Chem. 1997;  43 453-457
• 18 Viegas T MRF, Gomes S, Ezabella M, Toledo S PA, Abelin N MA. Comparison of omeprazole-induced calcitonin stimulation and calcium infusion tests in the diagnosis and follow up of patients with medullary thyroid carcinoma.  Arq Bras Endocrinol Metab. 2000;  44 (suppl 1) 173
• 19 Santoro M, Carlomagno F, Romano A, Bottaro D P, Dathan N A, Grieco M. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and 2B.  Science. 1995;  267 381-383
• 20 Huang S C, Koch C A, Vortmeyer A O, Pack S D, Lichtenauer U D, Mannan P, Lubensky I A, Chrousos G P, Gagel R F, Pacak K, Zhuang Z. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas.  Cancer Res. 2000;  60 6223-6226
• 21 Gagel R F, Levy M L, Donovan D T, Alford B R, Wheeles T, Tschen J A. Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis.  Ann Intern Med. 1989;  111 802-806
• 22 Ceccherini I, Romei C, Barone V, Pacini F, Martino E, Loviselli A, Pinchera A, Romeo G. Identification of the Cys634→Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis.  J Endocrinol Invest. 1994;  17 201-204
• 23 Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R F, van Amstel H K, Lips C J, Nishisho I, Takai S I, Marsh D J, Robinson B G, Frank-Raue K, Raue F, Xue F, Noll W W, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy G N, Mulligan L M. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET mutation Consortium analyses.  JAMA. 1996;  276 1575-1579
• 24 Sanchez B, Robledo M, Biarnes J, Saez M E, Volpini V, Benitez J, Navarro E, Ruiz A, Antinolo G, Borrego S. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.  J Med Genet. 1999;  36 68-70
• 25 Gagel R F, Tashjian A H Jr, Cummings T, Papathanasopoulos N, Kaplan M M, DeLellis R A, Wolfe H J, Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience.  N Engl J Med. 1988;  318 478-484
• 26 Gagel R F, Cote G J, Martins Bugalho M J, Boyd A E 3rd, Cummings T, Goepfert H, Evans D B, Cangir A, Khorana S, Schultz P N. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A.  J Intern Med. 1995;  238 333-341
• 27 Easton D F, Ponder M A, Cummings T, Gagel R F, Hansen H H, Reichlin S, Tashjian A H Jr, Telenius-Berg M, Ponder B A. The clinical and screening age-at-onset distribution for the MEN-2 syndrome.  Am J Hum Genet. 1989;  44 208-215
• 28 Lips C J, Landsvater R M, Hoppener J W, Geerdink R A, Blijham G, van Veen J M, van Gils A P, de Wit M J, Zewald R A, Berends M J, Beemer F A, Brouwers-Smalbraak J, Jansen R PM, van Amstel H KP, van Vroonhoven T JMV, Vroom T M. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A.  N Engl J Med. 1994;  331 828-835
• 29 Decker R A, Peacock M L, Borst M J, Sweet J D, Thompson N W. Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete?.  Surgery. 1995;  118 257-263
• 30 Gagel R F, Cote G J. Decision making in multiple neoplasia type 2.  Adv Endocrinol Metab. 1994;  5 1-18
• 31 Gagel R F. Multiple endocrine neoplasia. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds) Williams Textbook of Endocrinology. WB Saunders Philadelphia; 1998